Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Tempest Therapeutics (TPST) has received Orphan Drug Designation (ODD) from the FDA for TPST-1495, its dual receptor inhibitor of prostaglandin signaling, for treating Familial Adenomatous Polyposis (FAP). The designation marks a significant milestone for the company's second clinical program.
A Phase 2 study of TPST-1495 in FAP patients is scheduled to commence in 2025, led by the Cancer Prevention Clinical Trials Network with National Cancer Institute Division of Cancer Prevention funding. Study results are anticipated in 2026.
Tempest Therapeutics (TPST) ha ricevuto la designazione di farmaco orfano (ODD) dalla FDA per TPST-1495, il suo inibitore a doppio recettore della segnalazione delle prostaglandine, destinato al trattamento della Poliposi Adenomatosa Familiare (FAP). Questa designazione rappresenta un traguardo importante per il secondo programma clinico dell'azienda.
Uno studio di Fase 2 su TPST-1495 nei pazienti con FAP è previsto per il 2025, guidato dalla Cancer Prevention Clinical Trials Network con il finanziamento della Divisione di Prevenzione del Cancro del National Cancer Institute. I risultati dello studio sono attesi per il 2026.
Tempest Therapeutics (TPST) ha recibido la Designación de Medicamento Huérfano (ODD) por parte de la FDA para TPST-1495, su inhibidor de doble receptor de la señalización de prostaglandinas, para el tratamiento de la Poliposis Adenomatosa Familiar (FAP). Esta designación representa un hito importante para el segundo programa clínico de la compañía.
Un estudio de Fase 2 de TPST-1495 en pacientes con FAP está programado para comenzar en 2025, dirigido por la Cancer Prevention Clinical Trials Network con financiamiento de la División de Prevención del Cáncer del National Cancer Institute. Se esperan resultados del estudio en 2026.
Tempest Therapeutics (TPST)는 희귀의약품 지정(ODD)을 FDA로부터 받았습니다. TPST-1495는 프로스타글란딘 신호 전달의 이중 수용체 억제제로, 가족성 선종성 용종증(FAP) 치료에 사용됩니다. 이 지정은 회사의 두 번째 임상 프로그램에 중요한 이정표가 됩니다.
FAP 환자를 대상으로 한 TPST-1495의 2상 임상시험은 2025년에 시작될 예정이며, 국립암연구소 암예방부서의 자금 지원을 받는 암예방 임상시험 네트워크가 주도합니다. 연구 결과는 2026년에 발표될 예정입니다.
Tempest Therapeutics (TPST) a reçu la désignation de médicament orphelin (ODD) de la FDA pour TPST-1495, son inhibiteur à double récepteur de la signalisation des prostaglandines, destiné au traitement de la polypose adénomateuse familiale (FAP). Cette désignation représente une étape importante pour le deuxième programme clinique de la société.
Une étude de phase 2 de TPST-1495 chez des patients atteints de FAP est prévue pour débuter en 2025, dirigée par le Cancer Prevention Clinical Trials Network avec un financement de la Division de la Prévention du Cancer du National Cancer Institute. Les résultats de l'étude sont attendus en 2026.
Tempest Therapeutics (TPST) hat von der FDA die Orphan Drug Designation (ODD) für TPST-1495 erhalten, einen dualen Rezeptor-Inhibitor der Prostaglandin-Signalisierung, zur Behandlung der Familiären Adenomatösen Polyposis (FAP). Diese Designation stellt einen bedeutenden Meilenstein für das zweite klinische Programm des Unternehmens dar.
Eine Phase-2-Studie mit TPST-1495 bei FAP-Patienten soll 2025 beginnen, geleitet vom Cancer Prevention Clinical Trials Network mit Finanzierung durch die Division of Cancer Prevention des National Cancer Institute. Die Studienergebnisse werden für 2026 erwartet.
- FDA granted Orphan Drug Designation for TPST-1495
- Phase 2 trial fully funded by National Cancer Institute
- Second clinical program achieving regulatory milestone
- Phase 2 data not expected until 2026
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP).
“Receiving orphan drug designation for TPST-1495, our second clinical program, is a significant milestone in our mission to bring innovative therapies to patients with unmet medical need,” said Stephen Brady, President and CEO of Tempest. “This designation for the treatment of FAP underscores Tempest’s mission to make a meaningful difference in the lives of patients and builds on the momentum from prior designations received for amezalpat in hepatocellular carcinoma.”
A Phase 2 study evaluating TPST-1495 in patients with FAP is set to begin this year, conducted by the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (NCI) Division of Cancer Prevention. Data from this study are expected in 2026.
About Familial Adenomatous Polyposis
FAP is a high-risk inherited syndrome associated with the development of cancer in affected patients and has no approved medical therapies. In the US, the disease affects approximately one in 5,000 to 10,000 individuals2. FAP is caused by autosomal dominant inactivating mutations in the tumor suppressor gene APC. Patients with FAP develop large numbers of adenomatous polyps throughout the gastrointestinal tract, often starting in their teenage years. These growths have a high risk of malignant transformation and can give rise to invasive cancers of the colon, stomach, duodenum, rectum, and other tissues. Standard of care treatment for patients with FAP is surgical removal of the colon (colectomy) early in life to reduce the likelihood of cancer development. Even after colectomy, patients must receive careful surveillance for development of cancer elsewhere in the GI tract throughout their lifetime. While surgical management and surveillance have improved the prognosis for patients with FAP, cancer remains a major cause of death for patients with FAP.
| 1 | If approved by the FDA | |
| 2 | Rarediseases.org/rare-diseases/familial-adenomatous-polyposis/ | |
About Orphan Drug Designation
The FDA's Orphan Drug Designation program provides orphan status to therapies intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. This designation provides certain benefits, including tax credits for qualified clinical testing, waiver or partial payment of FDA application fees and seven years of market exclusivity, if approved.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined under the federal securities laws, that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Forward-looking statements contained in this press release include but are not limited to statements relating to: the initiation, timing and results of the Phase 2 study for TPST-1495; and the ability of TPST-1495 to benefit from the ODD designation, including potential tax credits and market exclusivity. Any forward-looking statements in this press release are based on Tempest Therapeutics’ current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks relating to: changes in the regulatory environment resulting in potentials delays in the clinical development and regulatory approval of our product candidates, including TPST-1495; the volatility and uncertainty in the capital markets for biotechnology companies; and our ability to raise additional capital or other pursue our plan to identify and complete a strategic transaction on attractive terms or at all. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on March 27, 2025, as well as in other filings the company may make with the SEC in the future. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.
Investor & Media Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
| i | If approved by the FDA |
FAQ
What is the significance of FDA's Orphan Drug Designation for TPST-1495?
When will Tempest's Phase 2 trial for TPST-1495 in FAP patients begin?
Who is funding the Phase 2 trial of TPST-1495?
What is TPST-1495's mechanism of action for treating FAP?
